Chronic Kidney Disease–Mineral and Bone Disorders (CKD-
MBD) Market
Chronic Kidney Disease–Mineral and Bone Disorders
(CKD-MBD) Market Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size and Growth
The Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market is expanding due to increasing CKD prevalence and growing awareness of associated complications. The global CKD-MBD market size is projected to reach approximately $2 billion by 2025, driven by advancements in treatment options and rising affordability of therapies.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Akebia
◍ Astellas
◍ Takeda
◍ Vifor
◍ Abbvie
◍ Fresenius
◍ Abbott
◍ Novadiol
◍ Japan Tobacco Company
◍ Daiichi-Sankyo
◍ Shield
◍ Spectrum
◍ OPKO
◍ Ardelyx
◍ Sanofi Genzyme
◍ Amgen
The CKD-MBD market features key players like Akebia, Astellas, and Amgen, focusing on innovative therapies and market expansion. Companies invest in R&D and collaboration to enhance treatment options. Sales figures: Amgen reported $23 billion (2022), AbbVie $58 billion (2021), and Fresenius $38 billion (2021), demonstrating significant market impact. Request Sample Report
Market Segmentation
By Application
◍ Hospital Pharmacies
◍ Retail Pharmacies
◍ Online Pharmacies
◍ Drug Stores
By Product
◍ Control Hyperphosphatemia
◍ Maintain Blood Calcium Levels
◍ Control PTH Level ◍ Correct Acidosis ◍ Other
◍ Other Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
